NCT03279302 is a Phase 1 clinical trial of Glepaglutide in Healthy Subjects, sponsored by Zealand Pharma.

Who is sponsoring NCT03279302?

NCT03279302 is sponsored by Zealand Pharma.

What drugs are being tested in NCT03279302?

Interventions in NCT03279302: Glepaglutide.

What condition does NCT03279302 study?

NCT03279302 studies Healthy Subjects.

Is NCT03279302 still recruiting?

NCT03279302 is currently completed. Last updated 22 December 2017.

Last reviewed 2017-12-22 · How we verify

NCT03279302

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Completed Phase 1 Last updated 22 December 2017

What this trial tests

Phase 1 trial testing Glepaglutide in Healthy Subjects in 75 participants. Completed in 18 December 2017.

Timeline

4 September 2017

Primary endpoint
18 December 2017

18 December 2017

Quick facts

Lead sponsor	Zealand Pharma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	4 September 2017
Primary completion	18 December 2017
Estimated completion	18 December 2017
Sites	1 location across United States

Drugs / interventions tested

Glepaglutide — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Zealand Pharma — full company profile →

Who can join

Adults 18 to 60, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of glepaglutide and its primary active metabolites following once-daily and once-weekly subcutaneous (SC) injections and after a single intravenous (IV) infusion in healthy subjects. Glepaglutide is a proposed International Nonproprietary Name for ZP1848

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.
Agersnap MA, Sonne K, Knudsen KM, Knudsen CB, et al · · 2022 · cited 9× · PMID 36323988 · DOI 10.1007/s40261-022-01210-1

Verify or expand the search:

Other trials of Glepaglutide

Trials testing the same drug.

NCT07197944 — Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS · Phase 3 · recruiting
NCT04991311 — The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syn · Phase 3 · completed
NCT04318743 — A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector. · Phase 1 · completed
NCT04178447 — Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function · Phase 1 · completed

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Zealand Pharma trials

Trials by the same sponsor.

NCT07197944 — Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS · Phase 3 · recruiting
NCT07338214 — Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations · Phase 1 · completed
NCT07228403 — Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome · Phase 3 · enrolling by invitation
NCT06926842 — Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) · Phase 2 · active not recruiting
NCT07076030 — Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03279302 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zealand Pharma
Last refreshed: 22 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03279302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing